Generative AI Visibility Report
How LLMs See the
GLP-1 CDMO Market
The GLP-1 CDMO market has become one of the most commercially dynamic segments in biopharmaceutical outsourcing. Demand for GLP-1 therapies has elevated the strategic importance of peptide synthesis capacity, peptide API manufacturing, sterile injectable production, fill-finish capability, and the ability to scale technically complex programs under tightening regulatory scrutiny. Sponsors, investors, commercial teams, and technical decision-makers are increasingly using AI systems to research this space to identify credible partners, compare capabilities, and form early impressions of the competitive landscape.
But these systems are not neutral directories. They construct a distinct narrative about the market, deciding which companies surface most often, which capabilities are associated with them, and who gets recommended when it matters most.
This report analyzes how leading generative AI systems currently interpret the GLP-1 CDMO landscape. Built from AI calls across ChatGPT, Claude, and Gemini, using a number of market-specific prompts run across three providers it maps which organizations dominate the AI-generated conversation, how capabilities are distributed across competitors, where the narrative is stable, and where meaningful opportunity remains.
But these systems are not neutral directories. They construct a distinct narrative about the market, deciding which companies surface most often, which capabilities are associated with them, and who gets recommended when it matters most.
This report analyzes how leading generative AI systems currently interpret the GLP-1 CDMO landscape. Built from AI calls across ChatGPT, Claude, and Gemini, using a number of market-specific prompts run across three providers it maps which organizations dominate the AI-generated conversation, how capabilities are distributed across competitors, where the narrative is stable, and where meaningful opportunity remains.
What This Report Reveals
Who AI considers the leaders
Which companies consistently surface when AI systems explain the GLP-1 CDMO market and how strongly their positions hold across providers and query types.
Which companies consistently surface when AI systems explain the GLP-1 CDMO market and how strongly their positions hold across providers and query types.
How capabilities are associated with competitors
Which organizations are most closely associated with peptide synthesis, peptide API manufacturing, large-scale peptide production, injectable manufacturing, and fill-finish services and which of those associations are contested.
Which organizations are most closely associated with peptide synthesis, peptide API manufacturing, large-scale peptide production, injectable manufacturing, and fill-finish services and which of those associations are contested.
Where the market narrative is strongest or fragmented
Areas where AI systems agree on leadership and where competitive positioning remains fluid enough to be influenced.
Areas where AI systems agree on leadership and where competitive positioning remains fluid enough to be influenced.
Which companies gain visibility through recommendations
When AI systems are asked to suggest GLP-1 CDMO partners, which organizations are surfaced and how that differs from general visibility.
When AI systems are asked to suggest GLP-1 CDMO partners, which organizations are surfaced and how that differs from general visibility.
Where strategic opportunities exist
Capabilities and narrative spaces — including pricing transparency, regulatory differentiation, SPPS, and fill-finish where the market story is not yet owned.
Capabilities and narrative spaces — including pricing transparency, regulatory differentiation, SPPS, and fill-finish where the market story is not yet owned.
Why This Matters
AI is becoming a market gatekeeper
When decision-makers begin evaluating GLP-1 CDMO partners, they increasingly ask AI first. That means the way generative systems represent this market can shape:
- Which companies are discovered early in the research process - How technical capabilities are interpreted and compared - Which organizations appear credible and differentiated - And who gets recommended before a human ever reaches out The GLP-1 CDMO segment is one of the most scrutinized in biopharmaceutical outsourcing right now. High demand, constrained capacity, and regulatory complexity make CDMO selection high-stakes. Understanding how AI systems represent this market and where your company sits within that representation is becoming a meaningful part of competitive positioning.
When decision-makers begin evaluating GLP-1 CDMO partners, they increasingly ask AI first. That means the way generative systems represent this market can shape:
- Which companies are discovered early in the research process - How technical capabilities are interpreted and compared - Which organizations appear credible and differentiated - And who gets recommended before a human ever reaches out The GLP-1 CDMO segment is one of the most scrutinized in biopharmaceutical outsourcing right now. High demand, constrained capacity, and regulatory complexity make CDMO selection high-stakes. Understanding how AI systems represent this market and where your company sits within that representation is becoming a meaningful part of competitive positioning.
Explore How AI Views the GLP-1 CDMO Market
Download the full report to see how generative AI systems currently interpret the GLP-1 CDMO space including Share of Voice rankings, Narrative Strength scores for the top 30 companies, capability ownership across peptide synthesis and manufacturing, recommendation dominance, source influence, fragility signals, and the highest-priority opportunities for narrative improvement.
Download the full report to see how generative AI systems currently interpret the GLP-1 CDMO space including Share of Voice rankings, Narrative Strength scores for the top 30 companies, capability ownership across peptide synthesis and manufacturing, recommendation dominance, source influence, fragility signals, and the highest-priority opportunities for narrative improvement.
Heads up, Firefox users: Firefox's privacy features can sometimes partially or entirely block contact forms (especially in Private Browsing mode) causing the form to not work as-intended.
If you're unable to submit or do not see a form below, please try a different browser, temporarily disable
Enhanced Tracking Protection,
or email us directly with your inquiry:
contact@inflluent.com